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The TARGIT-A trial found
no significant difference be-
tween TARGIT-IORT and
EBRT in terms of local
recurrence of breast cancer
or breast cancer survival. In
this longitudinal, single-site
TARGIT-A substudy,
TARGIT-IORT had similar
cosmetic outcomes to EBRT
but better breast-related
quality of life, as reported by
patients. This was despite
this analysis being limited to
patients who had received
TARGIT-IORT as a separate
procedure by reopening the
wound (postpathology).Purpose: To report the first comprehensive investigation of patient-reported cosmesis
and breast-related quality of life (QOL) outcomes comparing patients randomized to
risk-adapted single-dose intraoperative radiation therapy (TARGIT-IORT) versus
external beam radiation therapy (EBRT) on the TARGIT-A trial.
Methods and Materials: Longitudinal cosmesis and QOL data were collected from a
subset of TARGIT-A participants who received TARGIT-IORT as a separate procedure
(postpathology). Patients completed a cosmetic assessment before radiation therapy
and annually thereafter for at least 5 years. Patients also completed the combined
European Organization for Research and Treatment of Cancer (EORTC) core ques-
tionnaire and Breast-Specific Module in addition to the Body Image after Breast
Cancer Questionnaire at baseline and annually thereafter. The combined EORTC ques-
tionnaires were also collected 3, 6, and 9 months after wide local excision.
Results: An ExcellenteGood cosmetic result was scored more often than a Faire
Poor result for both treatment groups across all time points. The TARGIT-IORT
patients reported better breast-related QOL than EBRT patients. Statistically and
clinically significant differences were seen at month 6 and year 1, with EBRT pa-
tients having moderately worse breast symptoms (a statistically significant differ-
ence of more than 10 in a 100-point scale) than TARGIT-IORT patients at these
time points.
Conclusion: Patients treated with TARGIT-IORT on the TARGIT-A trial have
similar self-reported cosmetic outcome but better breast-related QOL outcomes than
patients treated with EBRT. This important evidence can facilitate the treatment
decision-making process for patients who have early breast cancer suitable for
breast-conserving surgery and inform their clinicians.  2016 The Authors. Pub-
lished by Elsevier Inc. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Whole-breast external beam radiation therapy (EBRT)
delivered in 15 to 35 daily fractions over 3 to 7 weeks is
standard adjuvant treatment for women undergoing breast-
conserving surgery for early breast cancer (1, 2). External
beam radiation therapy may require temporary relocation
for women who are geographically isolated or unable to
travel daily (3). External beam radiation therapy can have
acute toxicities, such as erythema, edema, breast indura-
tion, and skin breakdown (4), and long-term toxicities,
including local pain, fibrosis, telangiectasia, and cosmetic
changes (4, 5). Approximately 1% to 2% may develop
pneumonitis, pulmonary fibrosis, cardiotoxicity, osteor-
adionecrosis, or secondary malignancies (4, 6, 7). Some
women choose to forego radiation therapy owing to the
inconvenience or potential toxicities, either accepting
increased recurrence risks or choosing mastectomy (8-10).
Targeted intraoperative radiation therapy (TARGIT-
IORT) allows delivery of radiation directly to tissues at the
site of the primary tumor in a single session at the time of
wide local excision (WLE) or shortly afterward. The
TARGIT-A trial compared TARGIT-IORT with conven-
tional EBRT. Five-year results found TARGIT-IORT to be
non-inferior to EBRT in terms of risk of local recurrence
overall and when delivered during WLE (prepathology)
(non-inferiority could not be established for postpathology,but the difference was not statistically significant), and
there was no difference in breast cancer survival (11).
Toxicities were low; TARGIT-IORT had significantly fewer
skin toxicities (0.5% vs 2%) but higher risk of post-
operative seromas (2% vs 0.8%) (12). Cosmesis analysis
utilizing digital photographs showed better outcomes with
TARGIT-IORT in the first year (13).
Targeted IORT is now considered an acceptable treat-
ment option in several countries, with delivery during WLE
(prepathology) being the preferred approach. Awareness of
cosmesis and quality of life (QOL) outcomes is paramount
when clinicians are discussing treatment options with pa-
tients, in particular when comparing treatments with similar
efficacy and survival. This substudy is the first compre-
hensive investigation of patient-reported cosmesis and
breast-related QOL outcomes comparing patients random-
ized to TARGIT-IORT versus EBRT on the TARGIT-A
trial.Methods and Materials
Patients and treatment
Between 2000 and 2012, TARGIT-A registered 3451 pa-
tients from 33 centers in 11 countries. Patients with early
breast cancer suitable for breast-conserving surgery were
Table 1 Baseline patient characteristics by treatment
Patient, treatment, and
tumor characteristics TARGIT-IORT EBRT
N (%) 60 (48) 66 (52)
Age (y)
Mean  SD 63  8.2 62  7.4
Range 50-83 50-80
Baseline assessments before
any surgery, n (%)
1 (2) 12 (18)
Baseline BMI (kg/m2),
mean  SD
29  5.5 30  5.9
Baseline BMI group* (BMI range in kg/m2) (%)
1, Underweight (<18.5) 0 0
2, Normal (18.5-24.99) 30 16
3, Overweight (25-29.99) 30 50
4, Obese (30þ) 40 34
Tumor size (mm),
mean  SD
10  4.2 11  5.0
<11 (%) 62 52
11-20 (%) 38 46
>21y (%) - 1.5
Tumor grade, n (%)
1 37 (62) 38 (57)
2 23 (38) 27 (41)
3y 0 1 (1.5)
Tumor type, n (%)
IDC 59 (98) 64 (97)
Mixed IDC/ILCy 1 (1.7) 2 (3)
Lesions, n (%)
1 60 (100) 65 (98)
2y 0 1 (1.5)
Extensive DCIS (>25% of
tumor þ inside and
out of tumor),y n (%)
0 4 (6.3)
ERþ 60 (100) 64 (97)
PRþ 44 (73) 52 (79)
ER and PRy 0 2 (3)
Positive nodesy 0 1 (1.5) (1 node)
Largest specimen length
(mm), mean  SD
89  37.2 89  38.4
Range (mm) 25-205 40-267
Extent of axillary surgery, n (%)
Nil 3 (5) 2 (3)
SLNBx 49 (82) 55 (83)
Clearance 8 (13) 9 (14)
Further surgery required, n (%)
SLNBx 2 (3.3) 2 (3)
Margins 2 (3.3) 7 (11)
Revision of scar 2 (3.3) 0
Radiation therapy dose
(Gy), range
16-33z 45-50.4
Fractions (range) 1 25 (25-28)
Boost given (20 Gy in 10
fractions), n (%)
N/A 11 (17)
Supraclavicular treatment,
n (%)
N/A 1 (1.5)
Chemotherapy,y n (%) 0 1 (1.5)
(continued)
Table 1 (continued )
Patient, treatment, and
tumor characteristics TARGIT-IORT EBRT
Baseline patient Harris
score (% excellente
good), mean  SD
85  0.36 82  0.39
Baseline BR23 QOL scores (range of possible scores),
mean  SD
Body Image (0-100)x 93  15.6 93  9.6
Breast Symptoms
(0-100)x
20  17.4 21  18.4
Sexual Function (0-100)k 22  21.1 19  20.1
Sexual Enjoyment
(0-100)k
49  34.3 52  19.7
Baseline BIABC QOL scores (range of possible scores),
mean  SD
Arm Concerns (5-25)x 9  2.5 9  2.9
Body Concerns (6-30)x 16  4.3 16  4.4
Body Stigma (15-75)x 30  8.4 33  7.6
Transparency (5-25)x 6  2.7 7  2.2
Abbreviations: BIABC Z Body Image After Breast Cancer Ques-
tionnaire; BMIZ body mass index; BR23Z Breast-Specific Module;
DCIS Z ductal carcinoma in situ; EBRT Z external beam radiation
therapy; ERZ estrogen receptor; IDCZ Invasive Ductal Carcinoma;
ILC Z Invasive Lobular Carcinoma; PR Z progesterone receptor;
QOL Z quality of life; SD Z standard deviation; SLNBx Z sentinal
lymph node biopsy; TARGIT-IORTZ targeted intraoperative radiation
therapy.
* See reference 14.
y Factors relevant only to the prepathology stratification.
z Dose to surface of applicator.
x Higher score denotes worse symptoms.
k Higher score denotes better functioning.
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IORT (50-kV X rays with INTRABEAM [Carl Zeiss,
Oberkochen Germany]) or conventional 3 to 7 weeks’
EBRT. The TARGIT-IORT patients with unfavorable pa-
thology also received EBRT in approximately 15% of
cases; however, these were excluded from this analysis.
This substudy includes 126 patients from 3 treatment
centers in Western Australia. Relevant ethics approvals
were obtained, and all participants provided written,
informed consent.
The TARGIT-IORT dose to 1 cm was 5 to 6 Gy (16-
33 Gy at applicator surface), and EBRT was conventional
3-dimensional conformal radiation therapy (45-50.4 Gy in
25-28 fractions).
Eligibility for Australian patients randomized to the
postpathology stratification was stricter than for the main
trial: unifocal invasive ductal (not lobular) <2-cm tumors,
node negative, hormone positive, limited ductal carcinoma
in situ, and lymphovascular negative disease. Fourteen
EBRT and 4 IORT patients in this analysis were random-
ized prepathology where these criteria did not apply, hence
some deviations are shown in Table 1.
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Patients were routinely assessed at baseline, that is, after
initial surgery but before receiving either TARGIT-IORT
(as a separate procedure) or EBRT, and annually thereafter
for 5 years using the instruments given below.
Cosmesis
The Global Harris Scoring System of Excellent, Good, Fair,
or Poor was used (15-17). Responses are dichotomized into
Excellent and Good (EG) or Fair and Poor (FP) categories
(Table E1; available online at www.redjournal.org). Harris
Scores were also completed by a radiation oncologist,
nurse, and an objective photographic measurement system
(BCCT.core); however, these data will be reported
separately.
Quality of life
The European Organization for Research and Treatment of
Cancer (EORTC) core quality of life questionnaire (QLQ-
C30), Breast-Specific Module (BR23), and the Body Image
after Breast Cancer Questionnaire (BIABC) were used. The
EORTC questionnaires were also collected 3, 6, and
9 months after WLE. These tools were chosen because of
their reliability, validity, and ongoing use in several inter-
national breast cancer trials (18-22).
The EORTC QLQ-C30 comprises 5 functional scales
(Physical, Role, Emotional, Cognitive, Social), 3 symptom
scales (Fatigue, Nausea/Vomiting, Pain), 6 single-item
scales, and a Global QOL scale (19, 23). The validated
EORTC QLQ-BR23 has 23 questions grouped into 5 do-
mains (Systemic Treatment Side Effects, Arm Symptoms,
Breast Symptoms, Body Image, Sexual Functioning) and 3
single-item domains for Sexual Enjoyment, Hair Loss, and
Future Perspectives (19, 23, 24).
The EORTC questionnaires were scored according to
guidelines, resulting in scores ranging from 0 to 100. A
high score signifies better functioning for functional do-
mains but poorer scores for symptom domains (19). The
focus of this analysis is on the BR23 module. Most ques-
tions relate to patient experience in the last week, except for
sexual functioning, which has a 4-week time frame.
The BIABC is composed of 6 domains: Vulnerability,
Body Stigma, Limitations, Body Concerns, Transparency,
and Arm Concerns. Scoring was in accordance with the
corrected scoring system (25). Higher scores signify worse
functioning across all domains. Each domain has a different
range of possible scores (21, 25, 26). All questions relate to
patient experience in the last 4 weeks.
Panel review of QOL domains
To reduce multiple testing and investigate only relevant
breast-related domains, we performed a hypothesis-
generating panel review of the 2 breast-specific question-
naires (BR23 and BIABC). The review was exploratory; we
wished to hypothesize which domains might show differ-
ences between patients having TARGIT-IORT versus EBRT.Ten health professionals from radiation and medical
oncology, surgery, nursing, and clinical trials who were
familiar with TARGIT-IORT and EBRT participated. A
domain was included in the analysis if it was scored as
relevant by at least 3 responders. Four domains were
identified from the BIABC questionnaire, and the range of
possible scores were as follows: Arm Concerns, because it
includes a question about breast pain (5-25), Body Con-
cerns (6-30), Body Stigma (15-75), and Transparency
(obviousness of cancer to others and concern about cancer-
related appearance) (5-25). Four domains were identified
from the BR23 questionnaire: Body Image, Breast Symp-
toms, Sexual Function, and Sexual Enjoyment.
Analysis and interpretation
Despite the panel review reducing the number of evaluable
QOL domains from 26 to 8, a large number of tests were
still required for the primary analysis. Statistical signifi-
cance was therefore set at P<.01 to account for multiple
comparisons (23, 27).
Clinical significance utilizing the Osoba method is dis-
cussed according to QOL reporting guidelines (23, 28, 29).
A difference of at least 10 points on a 100-point scale is
considered a minimal clinically meaningful change; a dif-
ference between 10 and 20 points is considered a moderate
effect; and differences over 20 are considered a large effect
(23, 30).
Sensitivity analyses were performed to investigate
robustness of the complete case data. The EORTC scoring
system allows domain scores to be calculated in 2 ways: (1)
only when all questions in that domain have been answered
(complete case analysis); and (2) when at least half of the
questions in the domain have been answered, allowing the
calculation of an average score for the domain (single
imputation with mean substitution) (19). Multiple imputa-
tion of missing data was also applied to both questionnaires
(19, 31-33). Given the similarities in outcomes across the 3
datasets, only the findings from the complete case analysis
are reported.
IBM-SPSS version 22 (SPSS, Chicago, IL) was used for
the following: scoring QOL questionnaires; nonparametric
analysis (Mann-Whitney U and c2) of raw unadjusted data;
and for multiple imputation and single imputation for the
sensitivity analyses. Generalized estimating equations with
a variable covariance structure were used for the longitu-
dinal dichotomized cosmesis endpoint, and linear mixed
models were used for the continuous longitudinal QOL
endpoints using SAS version 9.3 (SAS Institute, Cary, NC).Results
Of 385 Western Australian TARGIT-A patients, only
the first 152 consecutive patients were invited to partici-
pate in this substudy owing to resource constraints, with
6 declining participation. A further 20 were excluded
because of confounders that would render cosmesis data
TARGIT-A Cohort in Western Australia (n=385) 
Invited to participate in cosmesis and quality of life sub-study (n=152)
Excluded (n=26)
Analyzed (n=126)
Declined (n=6)
TARGIT-IORT then EBRT (n=9)
Pre-Pathology (n=1)
No Radiotherapy (n=2)
Contralateral Cancer (n=8)
Had received TARGIT-IORT (n=60)
Had received EBRT (n=66)
Fig. 1. CONSORT diagram. Abbreviations:
EBRT Z external beam radiation therapy; TARGIT-
IORT Z targeted intraoperative radiation therapy.
100
90
80
70
60
50
40
30
20
10
0
Overall GEE P=.14
Univariate chi2 at Yr 5 P=.042
TARGIT-IORT
EBRT
BL
85
82
Yr 2Yr 1 Yr 4Yr 3
90 90 90
77 78 68
Yr 5
74
78
79
80
Fig. 2. Proportion of patients self-reporting excel-
lentegood cosmesis. Abbreviations: EBRT Z external
beam radiation therapy; GEE Z generalized estimating
equation; TARGIT-IORT Z targeted intraoperative radia-
tion therapy.
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and EBRT (nZ9); (2) received TARGIT-IORT during
WLE (nZ1); (3) no radiation therapy given (nZ2); or (4)
history of contralateral disease (nZ8). This left 126
evaluable participants, of whom 60 had TARGIT-IORT and
66 had EBRT (Fig. 1).Participants and compliance
Compliance was very good and nearly identical across both
treatment groups; however, as expected in a longitudinal
study, compliance decreased over time (Table E2; available
online at www.redjournal.org). Sensitive domains relating
to sexual function had the worst compliance, with a range
of 21% to 81% missing data across time points. There were
no significant differences in baseline patient characteristics
between treatment groups (Table 1).Cosmesis
Despite a trend for greater proportions of TARGIT-IORT
patients self-reporting an Excellent-Good result compared
with EBRT patients overall, multivariate longitudinal
analysis did not reveal any statistically significant differ-
ences between treatment group at any time point (Fig. 2).
Models to test whether other factors (such as age, body
mass index, specimen size, EBRT boost, and additional
surgery) may have an impact revealed no other drivers of
self-reported cosmetic outcome (14). Univariate analysis
revealed that TARGIT-IORT patients had better cosmeticoutcome compared with EBRT patients at year 5, with 90%
and 68.4% scoring EG, respectively, (PZ.042) (Fig. 2).
QOL results
Mean baseline scores for the 8 QOL domains selected a
priori did not demonstrate any significant differences at the
P<.01 level between the 2 treatment groups (Table E3;
available online at www.redjournal.org). Exploratory anal-
ysis of Global QOL scores showed significantly better
scores for TARGIT-IORT patients at baseline (79.5
TARGIT-IORT, 70.3 EBRT, PZ.007).
Beyond baseline, TARGIT-IORT patients tended to fare
better than EBRT patients in terms of breast-related QOL.
Nonparametric testing revealed statistically significantly
better results consistently favoring the TARGIT-IORT
group in the Arm Concerns domain at year 1 (P<.0001)
(Table E4; available online at www.redjournal.org), and
months 6 and 9 and years 1, 3, and 4 (P<.001) of the Breast
Symptoms domain. A number of differences were also
considered clinically significant (Table 2).
Treatment (and its interaction with time) had a statisti-
cally and clinically significant impact on the Breast
Symptoms (PZ.006) and Arm Concerns (PZ.005) do-
mains, both favoring TARGIT-IORT (Table 3). Age was
also found to be a significant factor in the Body Image
(PZ.004) and Sexual Function (P<.001) domains, where
an increase in age was associated with worse body image
and sexual function. Time since treatment was found to
impact the Sexual Function domain, with lower scores seen
at the year 5 time point for both treatment groups
(PZ.008). The Sexual Enjoyment domain shows mixed
results suggesting an interaction between treatment and
time (P<.001), with TARGIT-IORT patients scoring worse
function from baseline to 6 months, then better function
from 9 months onward, with clinically significant differ-
ences at years 1, 3, and 4. Age-adjusted mean scores for
Table 2 Statistically and clinically significant differences in long-term QOL between TARGIT-IORT and EBRT
Domain Baseline 3 mo 6 mo 9 mo 1 y 2 y 3 y 4 y 5 y
Body Image .2 .5 .2 .4 .3 .3 .1 .8 .5
Breast Symptoms .6 .2 .000* (12) .001* (7.9) .000* (10.4) .010y (5.8) .000* (8.5) .001* (5.7) .014y (6.2)
Sexual Function .5 .2 .9 .9 .5 (18.8) .3 (15.8) .4 (15.7) .1 (22.1) .035* (11.3)
Sexual Enjoyment .7 .7 .3 .4 .013y (18.8) .091y (15.8) .036y (15.7) .028y (22.1) .6
Arm Concerns .5 n/a n/a n/a .000* (12.7) .2 .031y (7.5) .2 .4
Body Concerns 1 n/a n/a n/a .9 .7 .9 .4 .9
Body Stigma .05 n/a n/a n/a .5 .2 .2 .3 .2
Transparency .5 n/a n/a n/a .3 1 .1 .6 .1
Abbreviations as in Table 1.
Values in parentheses are the Osoba clinical significance score. Note that Osoba clinical significance is reached with a difference >10 on a 100-point
scale. All clinically and statistically significant differences favored TARGIT-IORT.
* Significant at the .01 P level (Mann-Whitney U test).
y Significant at the .05 P level.
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tails shown in Table E5 (available online at www
.redjournal.org).
Although the core EORTC questionnaire was not used in
the a priori analysis, we explored the Global QOL domain,
which contains 2 questions relating to overall health and
overall QOL, respectively. A higher score denotes better
Global QOL, and results revealed that TARGIT-IORT pa-
tients consistently scored higher scores than EBRT patients,
with statistically significant differences found at baseline, 3
and 6 months, and 1 year. Clinically significant differences
were seen at 3 and 6 months (moderate and minimal clin-
ical significance, respectively) (Fig. E1; available online at
www.redjournal.org).
Sensitivity analyses
All 3 approaches to analysis (complete case, single impu-
tation, multiple imputation) produced similar parameter
estimates and P values. Minor disagreement was seen in 2
domains of the BIABC questionnaire at the P<.05 level, butTable 3 Longitudinal mixed model regression P values, adjusted fo
Domain Age Treatment Tim
Body Image .004* (0.28) .8 .9
Breast Symptoms .2 <.001* (1.48) <.0
Sexual Function <.001* (1.15) .3 .0
Sexual Enjoyment .05 .5 .3
Arm Concerns .6 .021y (0.43) .0
Body Concerns .6 .6 .4
Body Stigma .3 .2 .5
Transparency .016y (0.05) .6 .4
Abbreviations as in Table 1.
Values in parentheses are the parameter estimates of TARGIT-IORT versus
decreases by this value. All significant findings favored the TARGIT-IORT gro
* Significant at the <.01 level.
y Significant at the <.05 level.no differences were seen at the P<.001 level. Specimen size
was significant (PZ.035) in the complete case analysis of
body stigma but insignificant in the multiple imputation
analysis (PZ.064). The treatment  time interaction of the
Arm Concerns domain was significant for the complete
case analysis (PZ.006) but insignificant in the multiple
imputation analysis (PZ.112).
The effect of missing data on the year-5 cosmesis scores
was tested by carrying forward the previous years’ result.
This increased the proportion of an EG score from 68.4% to
69% for the EBRT group and decreased the proportion
from 90% to 88% in the TARGIT-IORT group.Discussion
Intraoperative radiation therapy is a new way to offer
adjuvant breast radiation therapy, and few studies of
cosmesis and QOL have been reported (34-37). This
TARGIT-A substudy provides comprehensive patient-
reported results comparing postpathology TARGIT-IORTr age and time
e Treatment  time BMI
Specimen
size (mm)
.7 n/a n/a
01* .006* n/a n/a
08* .9 .027y (3.05) n/a
<.001* n/a n/a
02* .005* n/a n/a
.8 n/a n/a
.6 n/a .019y (0.038)
.4 n/a n/a
EBRT: for every 1 unit of the variable, the QOL domain increases or
up.
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Fig. 3. Age-adjusted mean quality of life scores. Abbreviations: BIABC Z Body Image After Breast Cancer Question-
naire; EBRTZ external beam radiation therapy; EORTCZ European Organization for Research and Treatment of Cancer;
TARGIT-IORT Z targeted intraoperative radiation therapy.
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impact breast symptoms, improving QOL.
Patients receiving TARGIT-IORT tended to self-report
better outcomes for both cosmesis and QOL, such that a
higher number scored an EG cosmetic result across all timepoints, and they experienced fewer symptoms and better
functioning in breast-related QOL.
The only significant difference in cosmesis was at year 5
(Excellent-Good scores were 68.4% for EBRT and 90% for
TARGIT-IORT [PZ.007], which coincidentally were the
Corica et al. International Journal of Radiation Oncology  Biology  Physics62lowest and highest scores reported by patients across all
time points). Study attrition as a potential cause of this
difference was ruled out by sensitivity analysis. Overall, the
proportion of patients scoring themselves as EG was high
and compares well to previous research, which has shown
that 70% to 80% of EBRT patients can expect an EG
cosmetic outcome (4).
Clinically and statistically significant findings were seen
at year 1 for Arm Concerns and at month 6 for Breast
Symptoms. At these time points, EBRT patients experienced
moderately higher levels of treatment-related symptoms,
including breast and arm pain, swelling, oversensitivity, and
skin problems. These findings are in keeping with the results
obtained from cross-sectional studies of QOL in TARGIT-A
patients in Germany (median follow-up 47 months; pre-
pathology patients) (35, 37) and toxicity results from
TARGIT-A (12).
The increase in self-reported breast symptoms in EBRT
patients observed 6 months after WLE, which subsided by
the ninth month, was most likely because patients had only
just finished their EBRT around this time, when waiting
times were on average 4.5 months (2.3-7.9 months) for
completion of EBRT. The TARGIT-IORT patients had
completed their treatment between 4 days and 4 months
after WLE, with the average completion time of
1.6 months. Given the lack of significant difference be-
tween breast symptoms reported at 3 months, TARGIT-
IORT patients had presumably recovered from their
procedure by the time the 3-month questionnaire was
administered, when EBRT patients were just starting radi-
ation therapy. By 6 months, TARGIT-IORT patients had
improved further in terms of breast side effects, but EBRT
patients who had recently ceased or were still receiving
treatment were experiencing the peak of treatment-related
side effects. By 9 months both treatment groups scored
better than baseline scores, which is in keeping with other
longitudinal international QOL studies of EBRT (22, 38).
Breast symptoms for both groups continued to decrease
over time, showing better results for both groups at 4 years
(4.2 for TARGIT-IORT and 9.9 for EBRT) when compared
with the German cohort (8.6 for TARGIT-IORT and 19.2
for EBRT) (37). A similar reduction in breast symptoms
over time was also seen in the START-A and -B trials,
which assessed breast symptoms for different regimens of
EBRT from baseline to year 5, and also QOL studies per-
formed in Australia/New Zealand and Canada that assessed
both short- and long-term QOL after EBRT (22, 38, 39).
In comparison with the 50-Gy EBRT arm of the START
trials, patients treated with TARGIT-IORT in the present
study reported fewer breast symptoms at months 6 and
years 1 and 5; however, the patients treated with EBRT in
the present study showed worse breast symptoms across all
follow-up time points compared with TARGIT-IORT
(39, 40).
Overall, patients treated with TARGIT-IORT reported
better Global QOL scores at every time point. Despite not
reaching clinical significance, it is worth noting thatTARGIT-IORT patients scored better Global QOL at
baseline (79.5) compared with the EBRT group (70.3,
PZ.007), who had a score similar to the baseline scores for
the 50-Gy EBRT group in the START trials (69.8) (40). The
administration of the baseline questionnaire in the present
study was performed after patients were randomized. We
may hypothesize that either patients randomized to the
TARGIT-IORT arm were actually experiencing better QOL,
or that simply being randomized to the single treatment
may have had a positive effect on their sense of well-being,
which improved reported QOL. Anecdotally, patients ran-
domized to TARGIT-IORTwere visibly relieved to not have
to endure the 6-week burden of EBRT, and patients ran-
domized to EBRT would often become visibly upset when
informed they drew the conventional arm (particularly
those who would need to relocate to the city for the dura-
tion of their treatment, leaving behind dependents, animals,
or other responsibilities). Statistically and clinically sig-
nificant differences seen between TARGIT-IORT and
EBRT at 3 and 6 months suggest that the impact of un-
dergoing extended treatment was reflected in Global QOL
scores of EBRT patients. The administration of the 3-month
BR23 generally coincided with the start of EBRT (the
median time to start EBRT was 7.5 days before 3-month
BR23). This may have contributed to the poorer Global
QOL scores in the EBRT group. Patients who received
TARGIT-IORT completed the 3-month BR23 a median of
47 days after treatment, hence they may have returned to
their usual routine by that time.
Sensitivity analyses comparing complete case, single
imputation, and multiple imputation datasets produced
similar outcomes. This similarity can be explained by
excellent completion rates and generally good health
exhibited by participants, which led to few occasions for
which imputation was required. Multiple imputation is
complex and time consuming and is not necessary with the
amount, type, and pattern of missingness experienced by
this dataset.
This analysis reports the experience of patients who
received TARGIT-IORT as a separate procedure after WLE
(postpathology). Internationally, TARGIT-IORT during
WLE (prepathology) is now the preferred approach, and we
would not anticipate that the concurrent procedure would
result in worse cosmetic or QOL outcomes. Because it is
reasonable to expect that cosmetic outcome and QOL
would be worse in patients who have an additional proce-
dure after WLE, this is a factor that would work against
finding better outcomes with TARGIT-IORT versus EBRT
in this study. Therefore, our findings of equal or better
outcomes in such patients are even more significant.Limitations and strengths
This substudy describes only a subset of TARGIT-A pa-
tients, with a mix of patients from the pre- and post-
pathology stratifications. Sensitivity analysis showed that
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exception of sensitive questions relating to sexual function
and intimacy, in which missing data are universal (19, 41).
On average, across each time point, 53% and 45% of
TARGIT-IORT and EBRT patients, respectively, were
sexually active, hence only half of the surveyed population
could offer a score for the Sexual Enjoyment domain (on
average 19 patients per group per time point). Such small
numbers may reduce the generalizability of the reported
findings for this domain, despite excellent compliance
rates. Furthermore, this study did not distinguish between
partnered and nonpartnered women, and information on
adjuvant hormonal therapy was not reviewed, hence mak-
ing it impossible to interpret whether a reduction in sexual
function was potentially related to these factors.
Although the results of this study show that TARGIT-
IORT and EBRT patients have similar long-term outcomes,
the main clinically significant differences were seen within
the first year. Collection of data at months 3, 6, and 9 after
WLE, which encompass the radiation therapy treatment
time frame, is therefore a strength of this study because
other studies using a cross-sectional approach miss out on
this valuable information. Consideration must be given to
the timing of assessment to facilitate interpretation. In this
study the significant date was WLE; however, radiation
therapy end date may have been easier to interpret.
Conclusion
Patients treated with TARGIT-IORT in the TARGIT-A trial
have better breast-related QOL outcomes than patients
treated with EBRT, despite receiving TARGIT-IORT as a
separate procedure (postpathology). Patients receiving
EBRT experience worse breast-specific symptoms such as
pain, swelling, oversensitivity, and skin problems during or
shortly after treatment. Cosmetic outcomes were similar
overall, but TARGIT-IORT patients had better cosmetic
outcomes than EBRT patients at 5 years. Recently published
meta-analysis data shows that partial breast irradiation such
as TARGIT-IORT leads to a reduction in mortality, thus
TARGIT-IORT would benefit patients both in terms of
quality and quantity of life (42). This evidence is important
for clinicians and patients because it can facilitate the
decision-making process regarding treatment options for
early breast cancer treatable with breast-conserving surgery,
particularly owing to the convenience of TARGIT-IORT,
which may better suit patient preferences for treatment.References
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